Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges (2014 - 2026)

Ani Pharmaceuticals has disclosed Amortization of Deferred Charges across 13 years of filings, most recently posting $358000.0 for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $358000.0, up 10.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 54.92% YoY), and the FY2025 annual result was $1.4 million, up 111.21% from the prior year.
• Amortization of Deferred Charges came in at $358000.0 for Q1 2026 at Ani Pharmaceuticals, up from $351000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $998000.0 in Q4 2022 to a low of $102000.0 in Q1 2024.
• The 5-year median for Amortization of Deferred Charges is $591000.0 (2023), against an average of $582176.5.
• Across the five-year window, Amortization of Deferred Charges jumped 224.13% in 2022 and sank 82.74% in 2024, its largest moves.
• Ani Pharmaceuticals' Amortization of Deferred Charges stood at $998000.0 in 2022, then dropped by 4.61% to $952000.0 in 2023, then tumbled by 66.07% to $323000.0 in 2024, then climbed by 8.67% to $351000.0 in 2025, then advanced by 1.99% to $358000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $358000.0 (Q1 2026), $351000.0 (Q4 2025), and $838000.0 (Q3 2025), per Business Quant data.